Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Next Previous
X
Search
Trial Profile

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zenocutuzumab (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Merus

    • Most Recent Events

    • 11 Feb 2024 Status changed from active, no longer recruiting to completed.
    • 20 Sep 2023 This trail has been completed in Netherland (End Date: 26 Jul 2023), according to European Clinical Trials Database record.
    • 25 Aug 2023 This trail has been completed in Belgium (End Date: 26 Jul 2023), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top